ribosomal protein S21Genealiases: HLDF · S21 · eS21
Q-omics provides the consensus-scored RPS21 profile across patient tissues and cancer cell-line models. RPS21 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS21 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPS21 protein abundance shows 24,522 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where RPS21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS21 survival associations across molecular data types. RPS21 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS21 RNA expression–survival associations across cancer types. High RPS21 expression shows unfavorable associations in LIHC, KIRP, ACC, KICH and PRAD, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS21 RNA expression.
This table summarizes RPS21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS21 shows higher tumor expression in KIRC, COAD, LIHC, KIRP, STAD and CHOL. The KIRC box plot shows higher RPS21 RNA expression in tumor versus normal tissue (log2 FC = +0.977, t-test p < 0.001).
This table shows molecular features associated with RPS21 in patient tissues and cancer cell lines. In patient samples, RPS21 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
